Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD66e APC

Anti-Hu CD66e APC

Regulatory status

RUO

Antigen

CD66e

Clone

CB30

Format

APC

Reactivity

Human

Application

FC (QC tested)

Excitation laser

red (633 nm)

Variant

0.1 mg

1A-479-C100

Ask for delivery term HERE

220.00 USD

0.025 mg

1A-479-C025

Delivery 1 week

110.00 USD

Variant

0.1 mg

1A-479-C100

Ask for delivery term HERE

220.00 USD

0.025 mg

1A-479-C025

Delivery 1 week

110.00 USD

Contact distributor

Product details

Description

References

SDS download

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody CB30 recognizes CD66e (CEA; 180-200 kDa), an extracellular cell surface-bound carcinoembryonic antigen mainly expressed on epithelial cells.

Application

FC (QC tested)

Reactivity

Human

Immunogen

Human carcinoembryonic antigen (CEA; CEACAM5)

Concentration

0.1 mg/ml

Preparation

Purified antibody is conjugated with activated allophycocyanin (APC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

CEACAM5, CEA

Antigen description

The CD66e (CEA; 180-200 kDa) is a member of carcinoembryonic antigens, immunoglobulin supergene family and consists of a single N domain (structural homology to the immunoglobulin variable) and six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3). Human CD66e is heavily glycosylated GPI anchored protein capable of both homophilic and heterophilic adhesion. Disease relevance: The CD66e may play a role in the process of metastasis of cancer cells. CD66e is found in serum and it is clinically used as a tumor marker for early detection of disease due to its expression in adenocarcinomas - potential target of tumor imaging and drug targeting.

Entrez Gene ID 1048

UniProt ID P06731

General references:

Oikawa S, Nakazato H, Kosaki G: Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence. Biochem Biophys Res Commun. 1987 Jan 30;142(2):511-8.
PubMed

Thompson JA, Grunert F, Zimmermann W: Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5(5):344-66. Review.
PubMed

Gangopadhyay A, Bajenova O, Kelly TM, Thomas P: Carcinoembryonic antigen induces cytokine expression in Kuppfer cells: implications for hepatic metastasis from colorectal cancer. Cancer Res. 1996 Oct 15;56(20):4805-10.
PubMed

Chen CJ, Li LJ, Maruya A, Shively JE: In vitro and in vivo footprint analysis of the promoter of carcinoembryonic antigen in colon carcinoma cells: effects of interferon gamma treatment. Cancer Res. 1995 Sep 1;55(17):3873-82.
PubMed

Product specific references:

Koga S, Oshima Y, Honkura N, Iimura T, Kameda K, Sato K, Yoshida M, Yamamoto Y, Watanabe Y, Hikita A, Imamura T: In vivo subcellular imaging of tumors in mouse models using a fluorophore-conjugated anti-carcinoembryonic antigen antibody in two-photon excitation microscopy. Cancer Sci. 2014 Oct;105(10):1299-306.
PubMed

Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, Mineno J, Takesako K, Kato T, Shiku H: Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology. 2016 Jul 25;5(9):e1211218.
PubMed